BENEFITS

We are pleased to invite you to GTCbio’s Drug Discovery Week Europe (DDWE) 2015, to be held on October 5-8, 2015 in Berlin, Germany. The Drug Discovery Week will feature our Biomarker Summit Europe 2015 and 2nd Next Generation Sequencing & Bioinformatics Conference that will take place over the course of the four days.

Biomarker Summit Europe 2015 consists of two back-to-back conferences and will address the latest developments in the biomarker arena from discovery to translation to commercialization. Presentations span across multiple disciplines and cover topics such as discovery and validation strategies, the challenges of clinical translation, novel technologies including next-generation sequencing, companion diagnostics, the health economics value of biomarkers, and reimbursement environment. Scientific data, case studies and discussions will be facilitated by key representatives from pharma, biotech, academia and the public sector.

The 2nd Next Generation Sequencing & Bioinformatics conference will provide attendees with a better understanding of developments in new next generation sequencing technologies alongside clinical applications. Sequencing the exome and genome continues to open doors for more community resources as technology expands. We can expect where NGS and bioinformatics are poised to make a big impact in, especially in the transition to the clinic where screening for mutations in congenital disorders and cancer will benefit the most. Because our access to genomic information is increasing, we will also discuss the best practices for data interpretation.

Drug Discovery Week Europe 2015 includes:• October 5-8, 2015: Biomarker Summit Europe 2015: Conference 1: 9th Biomarkers in Drug Discovery & Development Conference 2: 4th Biomarkers in Diagnostics

• October 5-7, 2015: 2nd Next Generation Sequencing & Bioinformatics

ABOUT

SPONSORSHIP OPPORTUNITIES

Our conferences are designed with our sponsors and exhibitors in mind: we create intimate and highly interactive environments so that they can maximize their reach and make long-lasting contacts. Our sponsors and exhibitors benefit from a few of the following:

• Sponsors/exhibitors will receive the delegate list a week before and a week after the conference.

• Exhibit space is shared between all conferences, providing sponsors/exhibitors access to delegates at all conferences. Exhibitors are located in the same room where all networking functions take place. The coffee, snack stations, breakfast, and reception all occur in this room.

• Your corporate logo will be placed on the cover page of the conference brochures, the proceedings given to all conference delegates, and on the presentation screen during all breaks to enhance your company’s visibility at the event. Your logo will also be placed on the conference website agenda linked to your website.

For sponsorship and exhibit opportunities, please contact:

Amber KempfAccount Executive

amber.kempf@gtcbio.com

SPONSORS

CORPORATE PARTNER

GOLD

SomaLogic’s breakthrough SOMAmer™ protein-binding reagents and SOMAscan™ proteomic assay technologies can efficiently, accurately and rapidly identify and quantify over 1,100 proteins. SomaLogic’s breadth and depth of coverage offers unprecedented power for biomarker discovery, diagnostics development, and pharmaceutical discovery and development.

Swedish company Olink Bioscience provides innovative solutions for human protein biomarker research. Proseek® Multiplex enables rapid, high-throughput immunoassay analysis, exceptional data quality, and minimal sample consumption. Disease-focused panels allow simultaneous analysis of 92 biomarkers with 1 µl of sample, and are available as kits or via our fee-for service offering.

Quartz Bio is a clinical bioinformatics service company specialised in exploratory biomarker data analyses. Quartz Bio employs scientists with longstanding experience in R&D and expertise in biology, biotechnology, statistics, and computer sciences. Quartz Bio outsourcing solutions are based on Reproducible Research principles and are tailored to support pharmaceutical companies in their Precision Medicine projects.

Lexogen is a transcriptomics and Next Generation Sequencing company, focusing on the development of technologies for complete transcriptome sequencing. Our portfolio includes QuantSeq 3’mRNA-Seq Library Prep Kit, SENSE Total RNA/mRNA-Seq Library Prep Kits, TeloPrime Full-Length cDNA Amplification Kit, SPLIT RNA Extraction Kit and SQUARE Technology for splice variants analysis.

Myriad RBM, Inc. is the world’s leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology platform. This platform provides pre-clinical and clinical researchers with reproducible and quantitative data for a few or hundreds of proteins in a cost-effective manner.

Using novel epigenetic technology, Epiontis provides precise and reproducible immunomonitoring services for clinical trials. The epigenetic PCR tests are based on in-house developed and IP protected markers specific for immune cell types (Treg, Th17, overall Tcells, etc.). Frozen whole blood or tissue can be used, permitting easy storage and logistics.

Eurofins Bioanalytical Services is a powerhouse large molecule -focused bioanalytical contract research organization. Since our formation in 2003, we have actively supported the immunogenicity, pharmacokinetic and biomarker testing needs of companies that develop biotherapeutics by combining our scientific expertise, capacity and regulatory knowledge.

Affimers are affinity proteins, based on a small protein scaffold engineered to bind with high specificity and affinity to a range of targets. With a 7 week custom service and an online catalogue, Affimers are used for various applications in diagnostics, drug/biomarker discovery, biotech R&D and as therapeutic agents.

AGENDA AT-A-GLANCE

Day 1 - Monday, October 5, 20158:008:55

9:00

9:45

10:35

11:05

12:20

13:50

15:30

16:00

18:10

8:00

9:00

10:40

11:10

12:25

13:25

15:30

Registration & Continental BreakfastWelcome & Opening Remarks

9th Biomarkers in Drug Discovery & Development 2nd Next Generation Sequencing & Bioinformatics

9th Biomarkers in Drug Discovery & Development

KEYNOTE PRESENTATION

Session IBiomarker Discovery & Identification Strategies

Session I:Biomarker Discovery & Identification Strategies (cont.)

Session II:Applications of Imaging Biomarkers

Session III:Safety, Efficacy, & PK/PD Biomarkers in Drug Development

Session III:Safety, Efficacy, & PK/PD Biomarkers in Drug Development

(cont.)

Session IV:Companion Diagnostics Development & Partnering

Session V:Biomarkers & Surrogate Endpoints for Clinical Trials

Session VI:Overcoming Challenges of Clinical Validation & Translation

Session VII:Big Data Analytics for Biomarkers Development

Session VII:Big Data Analytics for Biomarkers Development (cont.)

2nd Next Generation Sequencing & Bioinformatics

KEYNOTE PRESENTATION

Session INext Generation Sequencing Technologies for Precision

Medicine

Session I:Next Generation Sequencing Technologies for Precision

Medicine (cont.)

Session I:Next Generation Sequencing Technologies for Precision

Medicine (cont.)

Session II:Clinical Applications in NGS: Cancer Genomics

Session III:Clinical Applications in NGS: Congenital Disorders

Session IV:Big Data Analysis Approaches

Session V:Transcriptomics & RNA Sequencing

Afternoon Networking & Coffee Break

Evening Networking Reception & Poster Session

Lunch on Your Own

Morning Networking & Coffee Break

Day 2 - Tuesday, October 6, 2015

Continental Breakfast

Lunch Provided by GTCbio

Morning Networking & Coffee Break

All times are approximate and subject to changes without notice

Conference Concludes End of Day 2

AGENDA AT-A-GLANCE

Day 3 - Wednesday, October 7, 20158:008:55

9:00

9:45

10:35

11:05

12:20

13:30

15:10

15:40

17:25

8:00

9:00

10:40

11:15

12:30

Registration & Continental BreakfastWelcome & Opening Remarks

4th Biomarkers in Diagnostics 2nd Next Generation Sequencing & Bioinformatics

4th Biomarkers in Diagnostics

KEYNOTE PRESENTATION

Session I: Novel Diagnostic Technologies

Session I: Novel Diagnostic Technologies (cont.)

Session II:

New Diagnostic Biomarkers & Their Development

Session II:New Diagnostic Biomarkers & Their Development (cont.)

Session III:Health Economics Value of Biomarkers & Reimbursement

Environment

Session III:Health Economics Value of Biomarkers & Reimbursement

Environment (cont.)

Session IV:Next Generation Sequencing in the Clinic

Session V:Clinical Utility of Diagnostic Biomarkers

Session V:Clinical Utility of Diagnostic Biomarkers (cont.)

Session VII:Sequencing Analysis & Data Interpretation: Structural

Bioinformatics

Session VIII:Sequencing Analysis & Data Interpretation: Clinical

Bioinformatics

Afternoon Networking & Coffee Break

Evening Networking Reception & Poster Session

Lunch Provided by GTCbio

Morning Networking & Coffee Break

Day 4 - Thursday, October 8, 2015

Continental Breakfast

Conference Concludes

Morning Networking & Coffee Break

All times are approximate and subject to changes without notice

Conference Concludes

Hans LehrachMax Planck Institute for Molecular Genetics

Sergey LezhninMerck

Douglas MacdonaldCHDI Foundation

Sabrina MattoliAvail Biomedical Research Institute (ABRI)

Pierluigi MauriProteomics and Metabolomics Laboratory -CNR; Institute for Biomedical Technologies (ITB-CNR)

Gary MiddletonUniversity of Birmingham

Mohammad Afshar Ariana Pharma

Christoph BorchersUniversity of Victoria;UVic Genome BC Proteomics Centre

Daniel Cohen Pharnext SAS

Kevin Cox Imanova

Pia DavidssonAstraZeneca R&D

Corina Dana Dota AstraZeneca

For an updated speaker list visit: www.gtcbio.com/ddwe/speakers

KEYNOTE SPEAKER

Biomarkers for Predictive Lab2Clinics Modeling – Can Big Data Deliver?

Discovery of Biomarkers Predictive of GSI Response in Triple Negative Breast Cancer

9th Biomarkers in Drug Discovery & Development

Multiplex MRM and iMALDI: From Biomarker Validation to Clinical Assays and Companion Diagnostics

Session: Biomarkers & Surrogate Endpoints for Clinical Trials

Reducing Risk in Drug Development – The 3i’s of Molecular Imaging

A Strategy for the Identification of Translatable Huntingtin Lowering Biomarkers

Biomarker Assays Based on RNA Detection

Clinical Proteomics in Biomarker and Drug Discovery for Bench to Bed Side Strategy

Andreas SchuppertBayer Technology ServicesAachen University

Next Generation Sequencing: A Key Factor in the Personalization of Medicine

DISTINGUISHED SPEAKERS

The Challenge of Transforming Big Data into a Cancer Treatment Selection Tool (onco KEM®) and Measuring Its Therapeutic Impact in an International Clinical Trial

Biomarker Discovery in Metabolic Diseases

Session: Biomarkers & Surrogate Endpoints for Clinical Trials

Session: Safety, Efficacy, and PK/PD Biomarkers in Drug Development

Anka EhrhardtBristol-Myers Squibb

Yasuhiro FunahashiEisai

David GaudenBlue Earth Diagnostics

Jakob Gjørret Dako, An Agilent Technologies Company

Ulrich Hoffmueller Epiontis GmbH

Daniel Hutcheson Roche

Sandra KirkwoodGenEngine Biotechnology

Andreas PoppAbbVie Deutschland

Hakon SaeteroyPre Diagnostic

Reinhard SchneiderLuxembourg Centre for Systems Biomedicine (LCSB) University of Luxembourg

Nicole Schneiderhan-MarraNMI Natural and Medical Sciences Institute at the University of Tuebingen

Lars VerschurenNetherlands Organization for Applied Scientific Research

Richardus VonkBayer Pharma AG

Diane WuestGNS Healthcare

DISTINGUISHED SPEAKERS (cont.)

Clinical Utility of Diagnostic Biomarkers in Drug Development for Alzheimer’s Disease

Session: Overcoming Challenges of Clinical Validation & Translation

RGM – From Target Side Effects to A New Indication – Anemia of Chronic Disease

Joint Efforts in the Qualification of Biomarkers for Drug Induced Organ Injury – An Overview of 6 Years IMI SAFE-T Consortium

9th Biomarkers in Drug Discovery & Development

Session: Biomarker Discovery & Identification Strategies

Alzheimer - A New Tool to Identify Early Stage Patients

For an updated speaker list visit: www.gtcbio.com/ddwe/speakers

Big Data and Computation Platform for the Detection of Biomarker Signatures as Part of the Luxembourg Parkinson’s Disease Cohort

Session: Big Data Analytics for Biomarkers Development

Session: Big Data Analytics for Biomarkers Development

Measures for Successful Partnering in Companion Diagnostic Development

Imaging in (Modern) Drug Development

Translational Science for Biomarkers of Lenvatinib in the Preclinical and Clinical Study

Any Biomarker – One Priority: Quality

Session: Overcoming Challenges of Clinical Validation & Translation

Wendy Alderton Abcodia

Markus Beier Comprehensive Biomarker Center

John BilelloRidge Diagnostics

Daniel ChelskyCaprion Proteomics

Joseph FerraraBoston Healthcare

Usha MenonUniversity College London

Sterghios MoschosUniversity of Westminster

Stephen PenningtonUniversity College Dublin

Bruce Quinn Foley Hoag

Philipp SchatzMetanomics Health

For an updated speaker list visit: www.gtcbio.com/ddwe/speakers

KEYNOTE SPEAKER

Exploring MicroRNA Biomarkers for Non-invasive Diagnosis

Towards the Objective Diagnosis and Treatment of Unipolar Depression

4th Biomarkers in Diagnostics

Defining the Clinical and Economic Value of NGS

From Molecular Biomarkers to Point of Care Molecular Diagnostics: Lessons from Ebola, Opportunities Beyond

Understand and Navigating Rapid Change for U.S. Diagnostics

The Future of Biomarkers in Diagnostics and Drug Development: An Industry Perspective

DISTINGUISHED SPEAKERSEarly Detection of Pancreatic Cancer

Application of Mass Spectrometry to Each Step in the Development of a Test for Benign vs. Malignant Pulmonary nodules

Development of a Blood Based Protein Signature to Stratify Patients for Prostate Cancer Treatment. From Discovery to Clinical Utility

Ovarian Cancer Screening – Role of Biomarkers

Clinical Metabolomics for the Early Detection of Heart Failure and Pancreatic Cancer

Miro Venturi Roche

Laszlo TakacsBiosystems International Kft. Hungary

Denise Uettwiller-GeigerJohn T. Mather Memorial Hospital

Kai Wang Institute for Systems Biology

Penny Wilson Innovate UK

Joachim Greuel Bioscience Valuation BSV GmbH

Franz Hessel SRH University Berlin

Masood Kamali-MoghaddamUppsala University

John LubniewskiHTG Molecular Diagnostics

For an updated speaker list visit: www.gtcbio.com/ddwe/speakers

DISTINGUISHED SPEAKERS (cont.)

Session: Health Economics Value of Biomarkers & Reimbursement Environment

From Multiple Modalities to a Single NGS Workflow: How Oncology Guideline Testing Can be Transformed

Use of Reticulocyte Hemoglobin (Ret-He/CHr) as a Biomarker of Erythropoiesis and Anemia Assessment

4th Biomarkers in Diagnostics

Discovery and Translation of Epitomics Biomarkers: Towards Diagnostics

Advanced Molecular Tools for Proteome Analyses and Biomarker Screening

Session: Next Generation Sequencing in the Clinic

Session: Health Economics Value of Biomarkers & Reimbursement Environment

Biomarkers and Precision Medicine, Embracing the Future

Wilhelm Ansorge Ecole Polytechnique Federale de Lausanne

Catherine ArnoldPublic Health England

Chiara BacchelliUniversity College London

Christian BeiselETH Zurich

Tim BonnertQiagen

Raffaele CalogeroUniversity of Torino

Rob KramsImperial College London

Dhavendra KumarInstitute of Medical Genetics, University Hospital of Wales

Nick LenchCongenica

Marie Just MikkelsenSamplix ApS

Max van MinCergentis

Satu NahkuriRoche Innovation Center Basel

For an updated speaker list visit: www.gtcbio.com/ddwe/speakers

KEYNOTE SPEAKER

Centralised NGS for Public Health Microbiology in the UK

Next Generation DNA Sequencing in Primary Immunodeficiency – A Glimpse of the Future of Personalised Medicine

2nd Next Generation Sequencing & Bioinformatics

Knowledge Based Analysis and Interpretation of Human NGS Data with QIAGEN Bioinformatics

Session: Clinical Applications in NGS: Congenital Disorders

Empowering Clinical Decision Support - Shortening the Route to Definitive Diagnosis in Rare Diseases

Sequencing a Founder Population

DISTINGUISHED SPEAKERSSession: Sequencing Analysis & Data Interpretation: Clinical Bioinformatics

Management of Big Data and Metadata in a Genomics Core Facility

Clinical Applications of NGS Diagnostic Gene Panels for Inherited Heart Disease

Targeted Enrichment for NGS – The Power of Focus

Kari StefanssondeCODE genetics

The Exosome Trascriptome as Reservoir for Biomarkers Discovery in Leukemia

Targeted Locus Amplification (TLA) for Targeted Complete Gene Sequencing & Haplotyping

Intercorporate Delivery of NGS Pipelines in Software Containers

Jamie PlattMolecular Pathology Laboratory Network

Timothy RavasiKing Abdullah University of Science and Technology

Alexander SeitzLexogen

Harpreet SinghIndian Council of Medical Research

David SmithMayo Clinic

Bernd TimmermannMax Planck Institute for Molecular Genetics

Verena TischlerSophia Genetics

Wei ChenMax Delbrück Center

Jim DowlingKTH – Royal Institute of Technology

Radoje DrmanacComplete Genomics

Sara GoodwinCold Spring Harbor Laboratory

Scott KahnIllumina

Christof von KalleNational Center for Tumor Diseases Heidelberg

Hans KartenGenalice

For an updated speaker list visit: www.gtcbio.com/ddwe/speakers

DISTINGUISHED SPEAKERS (cont.)

Neural Circular RNAs Are Derived from Synaptic Genes and Regulated by Development and Plasticity

Advances in Long Read Sequencing: The Emerging Role of Single Molecule, Long Read Sequencing in Cancer Genomics

Session: Sequencing Analysis & Data Interpretation: Structural Bioinformatics

Using Next Generation Sequencing to Understand the Different Roles that Human Papillomavirus Plays in the Development of Cancer

2nd Next Generation Sequencing & Bioinformatics

Bridging the Gaps in Precision Medicine through NGS in Pharma and Clinical Diagnostics

Session: Next Generation Sequencing Technologies for Precision Medicine

SIRVs – External Spike in Transcript Variant Controls for RNA-Seq

BiobankCloud: Scalable, Secure Storage and Analysis of Genomic Data

The Role of Molecular Information and Clinical Big Data in Precision Medicine

Session: Big Data Analysis Approaches

Genome Sequencing in Translational Oncology

GENALICE MAP: The Quality of High-Speed NGS Data Processing

Session: Next Generation Sequencing Technologies for Precision Medicine

NGS-Based Diagnostics: How to Achieve Top Analytical Performance and Guarantee Quality

Sean TyackeHorizon Discovery

Stefan WiemannGerman Cancer Research Center

Hywel WilliamsUniversity College London, Institute of Child Health

Andrzej KloczkowskiThe Ohio State University College of Medicine

Sebastian KmiecikUniversity of Warsaw

Andrzej KolinskiUniversity of Warsaw

Jan KomorowskiUppsala University

The Method for Protein-Peptide Molecular Docking

GOSgene – Gene Identification in Children with Rare Uncharacterised Diseases

For an updated speaker list visit: www.gtcbio.com/ddwe/speakers

DISTINGUISHED SPEAKERS (cont.)

2nd Next Generation Sequencing & Bioinformatics

Automated Methods for Modeling and Analysis of Protein Structures

Would You Get in a Plane with an Altimeter Which Had a CV of 10%? The Need for Improved Reproducibility within Biological Measurements

New Methods to Improve Modeling and Prediction of Protein Structure, Dynamics and Function

Opportunities and Challenges of Cancer Genome Sequencing

Understanding Cancer Expression Similarities and Differences: The Pan-Cancer Studies